Ginette-35
Cyproterone Acetate · Ethinylestradiol
Developed to mitigate androgen-related acne and hair growth to support clear skin and target hormone normalisation.
- Categories
- Women's Health · Contraception
- Active ingredients
- Cyproterone Acetate · Ethinylestradiol
- Route
- Oral use
- Form
- Tablet
- Strengths
- 0.035mg + 2mg
Prescription and consultation requirements for Ginette-35 vary by destination and are determined by the fulfilment partner.
Ginette-35 details
- Conditions
- Androgen-dependent Acne · Hirsutism
- Alternative names
- cyproterone, ethinyl estradiol
- Therapeutic class
- Oral Contraceptive and Antiandrogen
- Pharmacological class
- Androgen Receptor Antagonist, Estrogen Combination
- Minor side effects
- nausea; headache; breast tenderness
- Moderate side effects
- fluid retention; weight changes; mood swing
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 1–2 months
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Phenytoin; St. John's Wort
- Age restrictions
- Approved for post-menarche females.
Contraindications
pregnancy; history of deep vein thrombosis; severe hepatic disease; smoking over thirty-five years of age
Serious side effects
venous thromboembolism, requires immediate medical attention; stroke, requires immediate medical attention
Patient summary
developed to mitigate androgen-related acne and hair growth to support clear skin and target hormone normalisation.
Mechanism of action
Blocks androgen receptors to slow sebum gland activity while suppressing ovarian steroid synthesis.
Pregnancy and breastfeeding
TGA Category X: Highly contraindicated. Causes endocrine issues in fetus. Breastfeeding: Not recommended.